Resistin is an inflammatory marker of inflammatory bowel disease in humans
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: Resistin, a recently discovered adipokine, has been shown to be associated with inflammatory conditions such as insulin resistance, obesity, atherosclerosis and rheumatoid arthritis. We therefore hypothesized that (i) resistin levels may be elevated in patients with inflammatory bowel disease (IBD) and (ii) resistin levels may be associated with disease activity in IBD. METHODS: We addressed these questions by testing for associations between resistin plasma levels, inflammatory parameters and clinical disease activity in a case-control study with 235 patients with Crohn's disease (CD), 112 patients with ulcerative colitis (UC) and 144 healthy controls. RESULTS: Patients with IBD showed significantly higher resistin levels compared with controls (P<0.0001). In both, patients with CD and UC, resistin concentrations were significantly associated with elevated white blood cell count (P<0.0001), C-reactive protein (CRP) (P<0.0001) and disease activity (P< or =0.0001). In multivariate logistic regression analysis, resistin levels were identified as an independent predictor of active disease (odds ratio 1.014, 95% confidence interval 1.002-1.027, P=0.02) in patients with CD after adjusting for sex, age, body mass index, white blood cell count and CRP. In UC patients, resistin was associated with active disease in multivariate regression analysis after control for sex, age, body mass index and white blood cell count (odds ratio 1.015, 95% confidence interval 1.002-1.029, P=0.02). Addition of CRP, however, abolished this association. CONCLUSION: Resistin levels are an independent predictor of disease activity in patients with CD. Resistin may represent a novel link between inflammation and IBD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The hormone resistin links obesity to diabetes
Steppan, C. M., Bailey, S. T., Bhat, S., Brown, E. J., Banerjee, R. R., Wright, C. M., Patel, H. R., Ahima, R. S., & Lazar, M. A. (2001) · Nature · doi:10.1038/35053000 · Cited by 4,755
Adipokines: inflammation and the pleiotropic role of white adipose tissue
Trayhurn, P., & Wood, I. S. (2004) · British Journal of Nutrition · doi:10.1079/bjn20041213 · Cited by 2,210
Inflammatory pathways and insulin action
Hotamisligil, G. S. (2003) · International Journal of Obesity · doi:10.1038/sj.ijo.0802502 · Cited by 717
Cited by
Adipokines and Insulin Resistance
Rabe, K., Lehrke, M., Parhofer, K. G., & Broedl, U. C. (2008) · Molecular Medicine · doi:10.2119/2008-00058.rabe · Cited by 808
Self-citationObesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes
Singh, S., Dulai, P. S., Zarrinpar, A., Ramamoorthy, S., & Sandborn, W. J. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.181 · Cited by 452
The role of resistin as a regulator of inflammation: Implications for various human pathologies
Filková, M., Haluzík, M., Gay, S., & Šenolt, L. (2009) · Clinical Immunology · doi:10.1016/j.clim.2009.07.013 · Cited by 451
Insulin resistance in chronic kidney disease: a systematic review
Spoto, B., Pisano, A., & Zoccali, C. (2016) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00340.2016 · Cited by 450
Cytokine signature associated with disease severity in chronic fatigue syndrome patients
Montoya, J. G., Holmes, T. H., Anderson, J. N., Maecker, H. T., Rosenberg-Hasson, Y., Valencia, I. J., Chu, L., Younger, J. W., Tato, C. M., & Davis, M. M. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710519114 · Cited by 402
Metadata
- Authors
- Konrad, A., Lehrke, M., Schachinger, V., Seibold, F., Stark, R., Ochsenkühn, T., Parhofer, K. G., Göke, B., & Broedl, U. C.
- Venue
- European Journal of Gastroenterology & Hepatology
- Published
- 2007-12
- Volume
- 19
- Issue
- 12
- Pages
- 1070-1074
- ISSN
- 0954-691X (ISSN-L)
- OpenAlex
- W2037021965
- Cited by
- 148
- References
- 3
- FWCI
- 4.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.